» Articles » PMID: 16086947

Pathogenesis of Macular Edema with Branch Retinal Vein Occlusion and Intraocular Levels of Vascular Endothelial Growth Factor and Interleukin-6

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 2005 Aug 10
PMID 16086947
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine whether correlations between vascular endothelial growth factor (VEGF) or interleukin-6 (IL-6) contribute to the pathogenesis of macular edema in eyes of patients with branch retinal vein occlusion (BRVO).

Design: Retrospective case-control study.

Methods: Nineteen patients with macular edema with BRVO and seven patients with non-ischemic ocular disease (control group) were studied. The degree of retinal ischemia was evaluated in terms of the area of capillary non-perfusion, and the severity of macular edema was examined by optical coherence tomography. Aqueous humor samples were obtained at the time of combined vitrectomy and cataract surgery, and VEGF and IL-6 levels in aqueous humor and plasma were determined by enzyme-linked immunosorbent assay.

Results: Aqueous levels of VEGF (351 +/- 273 pg/ml) and IL-6 (7.10 +/- 6.51 pg/ml) were significantly elevated in patients with BRVO compared with the control patients (119 +/- 38.7 pg/ml and 2.27 +/- 1.11 pg/ml, respectively) (P = .0017 and P = .0052, respectively). Aqueous level of VEGF was significantly correlated with that of IL-6 (P = .0396), and aqueous levels of VEGF and IL-6 were correlated with the size of the BRVO non-perfused area (P < .0001 and P = .0331, respectively). Aqueous level of VEGF was correlated with the severity of macular edema (P = .0306).

Conclusions: VEGF and IL-6 may be involved in the pathogenesis of macular edema with BRVO. The increase in these cytokines might be used as a unique index of BRVO, through which we can determine the severity of the ischemic condition as being in a quiescent state or an exacerbation of macular edema.

Citing Articles

Effectiveness and cytokine profile of combined anti-vascular endothelial growth factor and corticosteroid therapy for chronic retinal vein occlusion.

Arai Y, Takahashi H, Inoda S, Sakamoto S, Kawashima H, Yanagi Y Graefes Arch Clin Exp Ophthalmol. 2025; .

PMID: 39825912 DOI: 10.1007/s00417-025-06738-4.


Real world experience of brolucizumab in recalcitrant macular edema in retinal vein occlusions (RVO's): 12 months follow up - A pilot study.

Narnaware S, Bawankule P, Raje D, Jagdhane P, Nagdeve R Indian J Ophthalmol. 2024; 72(12):1829-1832.

PMID: 39620686 PMC: 11727943. DOI: 10.4103/IJO.IJO_650_24.


Intravitreal Dexamethasone Implant Switch after Anti-VEGF Treatment in Patients Affected by Retinal Vein Occlusion: A Review of the Literature.

Vitiello L, Lixi F, Coppola A, Abbinante G, Gagliardi V, Salerno G J Clin Med. 2024; 13(17).

PMID: 39274219 PMC: 11395781. DOI: 10.3390/jcm13175006.


Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies.

Munk M, Ceklic L, Stillenmunkes R, Chaudhary V, Waheed N, Chhablani J Diagnostics (Basel). 2024; 14(17).

PMID: 39272767 PMC: 11394301. DOI: 10.3390/diagnostics14171983.


Systemic Risk Factors in Branch Retinal Vein Occlusion: a Comprehensive Review.

Garnavou-Xirou C, Bontzos G, Smoustopoulos G, Velissaris S, Papadopoulos A, Georgopoulos E Maedica (Bucur). 2024; 19(2):380-387.

PMID: 39188832 PMC: 11345058. DOI: 10.26574/maedica.2024.19.2.380.